{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:51:59Z","timestamp":1780624319977,"version":"3.54.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","interventional.theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.iccl.2016.08.007","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T07:01:56Z","timestamp":1479884516000},"page":"91-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting"],"prefix":"10.1016","volume":"6","author":[{"given":"Mikhail S.","family":"Dzeshka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccl.2014.07.009","article-title":"Antithrombotic and anticoagulant therapy for atrial fibrillation","volume":"32","author":"Dzeshka","year":"2014","journal-title":"Cardiol Clin"},{"issue":"1\u20132","key":"10.1016\/j.iccl.2016.08.007_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.20452\/pamw.2650","article-title":"Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part I","volume":"125","author":"Dzeshka","year":"2015","journal-title":"Pol Arch Med Wewn"},{"issue":"37","key":"10.1016\/j.iccl.2016.08.007_bib3","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Authors\/Task\u00a0Force\u00a0members","year":"2014","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1160\/TH15-09-0703","article-title":"Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease","volume":"115","author":"De Caterina","year":"2016","journal-title":"Thromb Haemost"},{"issue":"45","key":"10.1016\/j.iccl.2016.08.007_bib5","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.iccl.2016.08.007_bib6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/clc.22294","article-title":"Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2\u00a0-VASc, R2 CHADS2, HAS-BLED, ATRIA, and more)","volume":"37","author":"Dzeshka","year":"2014","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib7","first-page":"49","article-title":"Stroke and bleeding risk assessment: where are we now?","volume":"6","author":"Dzeshka","year":"2014","journal-title":"J\u00a0Atr Fibrillation"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1160\/TH15-12-0923","article-title":"Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review","volume":"116","author":"Overvad","year":"2016","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.iccl.2016.08.007_bib9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jacc.2015.06.1313","article-title":"Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications","volume":"66","author":"Dzeshka","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2016.08.007_bib10","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.amjcard.2015.08.049","article-title":"Stroke risk factors beyond the CHA2DS2-VASc Score: can we improve our identification of \u201dhigh stroke risk\u201c patients with atrial fibrillation?","volume":"116","author":"Szymanski","year":"2015","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.iccl.2016.08.007_bib11","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib12","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH15-03-0210","article-title":"The risks of risk scores for stroke risk assessment in atrial fibrillation","volume":"113","author":"Nielsen","year":"2015","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1160\/TH15-02-0154","article-title":"Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc\u00a0>\/=1, or higher?","volume":"113","author":"Olesen","year":"2015","journal-title":"Thromb Haemost"},{"issue":"14","key":"10.1016\/j.iccl.2016.08.007_bib14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"Lip","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cjca.2014.10.018","article-title":"Atrial fibrillation patients categorized as \u201dnot for anticoagulation\u201c according to the 2014 Canadian Cardiovascular Society algorithm are not \u201dlow risk\u201c","volume":"31","author":"Lip","year":"2015","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1160\/TH15-07-0565","article-title":"Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy","volume":"114","author":"Lip","year":"2015","journal-title":"Thromb Haemost"},{"issue":"21","key":"10.1016\/j.iccl.2016.08.007_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.iccl.2016.08.007_bib18","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjmed.2015.07.013","article-title":"Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF registry, Phase II","volume":"128","author":"Huisman","year":"2015","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A\u00a0prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.iccl.2016.08.007_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ahj.2015.10.028","article-title":"Racial\/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry","volume":"174","author":"Golwala","year":"2016","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib21","doi-asserted-by":"crossref","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.iccl.2016.08.007_bib22","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.114.014058","article-title":"Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study","volume":"131","author":"Lubitz","year":"2015","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.iccl.2016.08.007_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2459\/JCM.0000000000000241","article-title":"Stroke and death prediction with CHA2DS2-vasc score after myocardial infarction in patients without atrial fibrillation","volume":"16","author":"Podolecki","year":"2015","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2048872613517370","article-title":"Prognostic impact of atrial fibrillation in acute coronary syndromes: results from the ARIAM registry","volume":"3","author":"Almendro-Delia","year":"2014","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"7","key":"10.1016\/j.iccl.2016.08.007_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/hrt.2007.134486","article-title":"Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation","volume":"94","author":"Lopes","year":"2008","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib26","doi-asserted-by":"crossref","first-page":"e001006","DOI":"10.1161\/JAHA.114.001006","article-title":"Impact of atrial fibrillation on healthcare utilization in the community: the Atherosclerosis Risk in Communities study","volume":"3","author":"Bengtson","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1160\/TH14-07-0599","article-title":"Progress in interventional cardiology: challenges for the future","volume":"113","author":"Simsekyilmaz","year":"2015","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1160\/TH14-01-0032","article-title":"Fibrin clot properties and their modulation in thrombotic disorders","volume":"112","author":"Undas","year":"2014","journal-title":"Thromb Haemost"},{"issue":"15","key":"10.1016\/j.iccl.2016.08.007_bib29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.iccl.2016.08.007_bib30","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/europace\/euv269","article-title":"Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry","volume":"17","author":"Lip","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.iccl.2016.08.007_bib31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijcard.2015.11.090","article-title":"Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence?","volume":"203","author":"Ancedy","year":"2016","journal-title":"Int J Cardiol"},{"issue":"9872","key":"10.1016\/j.iccl.2016.08.007_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.iccl.2016.08.007_bib33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.iccl.2016.08.007_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"issue":"16","key":"10.1016\/j.iccl.2016.08.007_bib36","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.iccl.2016.08.007_bib37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tcm.2014.10.017","article-title":"Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?","volume":"25","author":"Dzeshka","year":"2015","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.iccl.2016.08.007_bib39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.iccl.2016.08.007_bib40","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Randomized evaluation of long-term anticoagulation therapy I. Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iccl.2016.08.007_bib41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.iccl.2016.08.007_bib42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.iccl.2016.08.007_bib43","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1160\/TH15-04-0298","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) in the cardiac catherisation laboratory: friends or foes?","volume":"114","author":"Htun","year":"2015","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.20452\/pamw.2711","article-title":"Patients with atrial fibrillation undergoing percutaneous coronary intervention: current concepts and concerns: part II","volume":"125","author":"Dzeshka","year":"2015","journal-title":"Pol Arch Med Wewn"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1160\/TH15-12-0955","article-title":"An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance","volume":"116","author":"Shahabi","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1160\/TH14-09-0814","article-title":"Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study","volume":"115","author":"Cerezo-Manchado","year":"2016","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib48","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1160\/TH15-01-0071","article-title":"Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis","volume":"114","author":"Belley-Cote","year":"2015","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib49","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1160\/TH15-10-0840","article-title":"Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry","volume":"115","author":"Hecker","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH15-04-0350","article-title":"Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study","volume":"115","author":"Martinez","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1160\/TH14-02-0161","article-title":"Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey","volume":"113","author":"Van Blerk","year":"2015","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1160\/TH15-05-0415","article-title":"Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide","volume":"115","author":"Douxfils","year":"2015","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib53","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH14-11-0982","article-title":"Reversal of anticoagulants: an overview of current developments","volume":"113","author":"Greinacher","year":"2015","journal-title":"Thromb Haemost"},{"issue":"22","key":"10.1016\/j.iccl.2016.08.007_bib54","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.iccl.2016.08.007_bib55","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib57","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1160\/TH14-10-0859","article-title":"Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula","volume":"113","author":"Sjogren","year":"2015","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1160\/TH15-02-0169","article-title":"Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists","volume":"114","author":"Ruiz-Ortiz","year":"2015","journal-title":"Thromb Haemost"},{"issue":"20","key":"10.1016\/j.iccl.2016.08.007_bib59","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2016.08.007_bib60","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib61","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"9994","key":"10.1016\/j.iccl.2016.08.007_bib62","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0140-6736(15)60657-2","article-title":"Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis","volume":"386","author":"Siontis","year":"2015","journal-title":"Lancet"},{"issue":"10016","key":"10.1016\/j.iccl.2016.08.007_bib63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0140-6736(15)00548-6","article-title":"Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial","volume":"387","author":"Sabate","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.iccl.2016.08.007_bib64","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iccl.2016.08.007_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw203","article-title":"Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study","author":"Naber","year":"2016","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.iccl.2016.08.007_bib66","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1253\/circj.CJ-14-0792","article-title":"Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"78","author":"Kiviniemi","year":"2014","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH14-12-1057","article-title":"Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery","volume":"114","author":"Capodanno","year":"2015","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH14-04-0305","article-title":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial","volume":"113","author":"Douketis","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2016.08.007_bib69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2015.01.056","article-title":"Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study","volume":"183","author":"Kiviniemi","year":"2015","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib70","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCULATIONAHA.114.011777","article-title":"Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"131","author":"Steinberg","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4244\/EIJY14M06_07","article-title":"Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial","volume":"11","author":"Dewilde","year":"2015","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib72","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH15-01-0061","article-title":"Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial","volume":"114","author":"Vranckx","year":"2015","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1160\/TH15-04-0355","article-title":"Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review","volume":"115","author":"Vries","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14423\/SMJ.0000000000000404","article-title":"Systematic review and meta-analysis of major cardiovascular outcomes for radial versus femoral access in patients with acute coronary syndrome","volume":"109","author":"Ruiz-Rodriguez","year":"2016","journal-title":"South Med J"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib75","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.amjcard.2015.10.039","article-title":"Meta-analysis of radial versus femoral access for percutaneous coronary interventions in non-ST-segment elevation acute coronary syndrome","volume":"117","author":"Bavishi","year":"2016","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cjca.2012.08.008","article-title":"Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation","volume":"29","author":"Ho","year":"2013","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib77","first-page":"391","article-title":"Health care burden of dyspepsia among nonvalvular atrial fibrillation patients","volume":"20","author":"Kim","year":"2014","journal-title":"J\u00a0Manag\u00a0Care\u00a0Spec Pharm"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib78","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.iccl.2016.08.007_bib79","first-page":"130060","article-title":"Thromboembolic complications of thyroid storm","volume":"2014","author":"Min","year":"2014","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"9","key":"10.1016\/j.iccl.2016.08.007_bib80","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4244\/EIJV10I9A174","article-title":"Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement","volume":"10","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib81","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s00380-014-0498-3","article-title":"Hybrid epicardial and endocardial ablation of a persistent atrial tachycardia arising from the marshall bundle: the importance of a detailed analysis of the local potentials","volume":"30","author":"Kuroki","year":"2015","journal-title":"Heart Vessels"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib82","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib83","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib84","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib85","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.amjcard.2011.10.004","article-title":"Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention","volume":"109","author":"Chan","year":"2012","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib86","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jelectrocard.2014.12.010","article-title":"Atrial fibrillation in patients admitted to coronary care units in western Sweden\u2014focus on obesity and lipotoxicity","volume":"48","author":"Gizurarson","year":"2015","journal-title":"J\u00a0Electrocardiol"},{"issue":"19","key":"10.1016\/j.iccl.2016.08.007_bib87","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.110.990192","article-title":"Atrial fibrillation and death after myocardial infarction: a community study","volume":"123","author":"Jabre","year":"2011","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.iccl.2016.08.007_bib88","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.amjcard.2009.06.055","article-title":"Prognostic impact of types of atrial fibrillation in acute coronary syndromes","volume":"104","author":"Lau","year":"2009","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.iccl.2016.08.007_bib89","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/eurheartj\/ehp213","article-title":"Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial","volume":"30","author":"Lopes","year":"2009","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.iccl.2016.08.007_bib90","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.amjmed.2012.04.006","article-title":"Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes","volume":"125","author":"Lopes","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.iccl.2016.08.007_bib91","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ijcard.2015.11.111","article-title":"Atrial fibrillation and long-term prognosis of patients with stable coronary heart disease: relevance of routine electrocardiogram","volume":"203","author":"Meyer","year":"2016","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.iccl.2016.08.007_bib92","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4244\/EIJV8I9A163","article-title":"Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents","volume":"8","author":"Pilgrim","year":"2013","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib93","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.amjcard.2013.09.016","article-title":"Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial)","volume":"113","author":"Rene","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.iccl.2016.08.007_bib94","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijcard.2015.02.004","article-title":"Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease","volume":"184","author":"Rohla","year":"2015","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib95","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2013.11.030","article-title":"Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry","volume":"170","author":"Ruff","year":"2014","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib96","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH13-04-0351","article-title":"Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation","volume":"110","author":"Bernard","year":"2013","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib97","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ageing\/afs121","article-title":"Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting","volume":"42","author":"Caballero","year":"2013","journal-title":"Age Ageing"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib98","first-page":"234","article-title":"Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?","volume":"9","author":"Dabrowska","year":"2013","journal-title":"Postepy Kardiol Interwencyjnej"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib99","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2013.08.005","article-title":"Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy","volume":"166","author":"Fosbol","year":"2013","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib100","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1253\/circj.CJ-09-0880","article-title":"Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation","volume":"74","author":"Gao","year":"2010","journal-title":"Circ J"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib101","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.amjcard.2009.03.053","article-title":"Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO])","volume":"104","author":"Gilard","year":"2009","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib102","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MCA.0000000000000242","article-title":"Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation","volume":"26","author":"Kang","year":"2015","journal-title":"Coron Artery Dis"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib103","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/eurheartj\/ehl488","article-title":"Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting","volume":"28","author":"Karjalainen","year":"2007","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib104","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.amjmed.2015.12.026","article-title":"Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease","volume":"129","author":"Lopes","year":"2016","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amjcard.2015.03.033","article-title":"Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry)","volume":"116","author":"Mennuni","year":"2015","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.iccl.2016.08.007_bib106","doi-asserted-by":"crossref","first-page":"P4093","DOI":"10.1093\/eurheartj\/eht309.P4093","article-title":"Outcomes in patients with atrial fibrillation undergoing coronary artery stenting with a low-moderate CHA2DS2VASc score: do they need anticoagulation?","volume":"34","author":"Mutuberria Urdaniz","year":"2013","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.iccl.2016.08.007_bib107","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","article-title":"Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy","volume":"102","author":"Rossini","year":"2008","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.iccl.2016.08.007_bib108","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.amjcard.2012.01.353","article-title":"Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry)","volume":"109","author":"Rubboli","year":"2012","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2016.08.007_bib109","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2007.11.035","article-title":"Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis","volume":"51","author":"Ruiz-Nodar","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCINTERVENTIONS.112.968792","article-title":"Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?","volume":"5","author":"Ruiz-Nodar","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"issue":"18","key":"10.1016\/j.iccl.2016.08.007_bib111","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/hrt.2009.167064","article-title":"Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study","volume":"95","author":"Sambola","year":"2009","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib112","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1253\/circj.CJ-15-0923","article-title":"Effects of triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification","volume":"80","author":"Sambola","year":"2016","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.iccl.2016.08.007_bib113","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV8I6A105","article-title":"Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score","volume":"8","author":"Smith","year":"2012","journal-title":"EuroIntervention"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib114","first-page":"362","article-title":"Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents","volume":"55","author":"Uchida","year":"2010","journal-title":"J\u00a0Cardiol"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cjca.2012.06.012","article-title":"Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib116","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/ccd.26234","article-title":"Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: a meta-analysis of observational studies","volume":"88","author":"Bavishi","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2010.11.019","article-title":"Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation","volume":"148","author":"Gao","year":"2011","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2016.08.007_bib118","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/clc.22411","article-title":"Antithrombotic regimens for patients taking oral anticoagulation after coronary intervention: a meta-analysis of 16 clinical trials and 9,185 patients","volume":"38","author":"Gao","year":"2015","journal-title":"Clin Cardiol"},{"issue":"13","key":"10.1016\/j.iccl.2016.08.007_bib119","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3760\/cma.j.issn.0366-6999.20130359","article-title":"Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis","volume":"126","author":"Saheb","year":"2013","journal-title":"Chin Med J"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1753944710391925","article-title":"Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation","volume":"5","author":"Singh","year":"2011","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.iccl.2016.08.007_bib121","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11239-014-1094-1","article-title":"Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review","volume":"38","author":"Washam","year":"2014","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib122","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.09-3083","article-title":"\u201dTriple therapy\u201c rather than \u201dtriple threat\u201c: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment","volume":"139","author":"Zhao","year":"2011","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.iccl.2016.08.007_bib123","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.2015.973847","article-title":"Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation","volume":"14","author":"Dzeshka","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"17","key":"10.1016\/j.iccl.2016.08.007_bib124","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1517\/14656566.2015.1104301","article-title":"Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation","volume":"16","author":"Dzeshka","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.iccl.2016.08.007_bib125","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.iccl.2016.08.007_bib126","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.iccl.2016.08.007_bib127","doi-asserted-by":"crossref","first-page":"e002587","DOI":"10.1161\/JAHA.115.002587","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial","volume":"5","author":"Xu","year":"2016","journal-title":"J\u00a0Am Heart Assoc"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816300906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745816300906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T20:33:26Z","timestamp":1749760406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745816300906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S2211745816300906"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.007","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2016.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}